Clinical Trial Update: A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study of filanesib (ARRY-520) in combination with carfilzomib in advanced multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• Filanesib (ARRY-520) (filanesib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Multiple Myeloma | Phase 2 | Status: COMPLETED